Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04326257 · ClinicalTrials.gov registry record · Phase 2
Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy
A Phase 2 study, sponsored by Dan Zandberg.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT04326257 is a Phase 2 study that has completed, run by Dan Zandberg. The registered enrollment target is 20 participants.
The verdict
NCT04326257, a Phase 2 study, has completed, sponsored by Dan Zandberg.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
In this Phase II trial of personalized immunotherapy in R/M HNSCC, gene expression of LAG3 and CTLA4 by RNA seq will be determined to select the appropriate agent (Ipilimumab or Relatlimab) to add to Nivolumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC) who have failed prior immunotherapy with anti-PD-1 or PD-L1 mAb therapy. The agent, either Ipilimumab or Relatlimab will be chosen based on the highest relevant immune gene expression (CTLA4 or LAG-3) as long as the minimum difference required is met.
Interventions
- DRUG Nivolumab+Relatlimab
- DRUG Nivolumab+Ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-05-14 |
| Est. Completion | 2024-08-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04326257
The ClinicalTrials.gov registry entry for NCT04326257 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dan Zandberg, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab+Relatlimab is the first listed.
NCT04326257 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04326257 about?
NCT04326257 is a clinical study titled "Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy". In this Phase II trial of personalized immunotherapy in R/M HNSCC, gene expression of LAG3 and CTLA4 by RNA seq will be determined to select the appropriate agent (Ipilimumab or Relatlimab) to add to Nivolumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck ...
What is the current status of trial NCT04326257?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2020-05-14. Estimated completion is 2024-08-12.
What interventions are being tested in trial NCT04326257?
The interventions under investigation include: Nivolumab+Relatlimab (DRUG), Nivolumab+Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT04326257?
This trial is sponsored by Dan Zandberg, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.